Head to Head Review: Aclarion (NASDAQ:ACON) and Todos Med (OTCMKTS:TOMDF)

Todos Med (OTCMKTS:TOMDF) and Aclarion (NASDAQ:ACON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider and Institutional Ownership

7.5% of Aclarion shares are owned by institutional investors. 0.8% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Todos Med and Aclarion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Todos Med	N/A	N/A	N/A
Aclarion	-9,517.11%	-52.31%	-49.79%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Todos Med and Aclarion, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Todos Med	0	0	0	0	0.00
Aclarion	1	0	0	0	1.00

Given Todos Med’s higher probable upside, analysts clearly believe Todos Med is more favorable than Aclarion.

Volatility and Risk

Todos Med has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Valuation and Earnings

This table compares Todos Med and Aclarion”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Todos Med	N/A	N/A	N/A	N/A	N/A
Aclarion	$80,000.00	34.32	-$7.23 million	($17.01)	-0.19

Todos Med has higher earnings, but lower revenue than Aclarion.

Summary

Aclarion beats Todos Med on 5 of the 9 factors compared between the two stocks.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.